-
1
-
-
0022899577
-
Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type
-
Summers W.K., Majovski L.V., Marsh G.M., Tachiki K., and Kling A. Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. N Engl J Med 315 (1986) 1241-1245
-
(1986)
N Engl J Med
, vol.315
, pp. 1241-1245
-
-
Summers, W.K.1
Majovski, L.V.2
Marsh, G.M.3
Tachiki, K.4
Kling, A.5
-
2
-
-
0032507788
-
Donepezil improves cognition and global funtion in Alzheimer disease
-
Donepexil Study Group
-
Rogers S.L., Doody R.S., Mohs R.C., Friedhoff L.T., and Donepexil Study Group. Donepezil improves cognition and global funtion in Alzheimer disease. Arch Intern Med 158 (1998) 1021-1031
-
(1998)
Arch Intern Med
, vol.158
, pp. 1021-1031
-
-
Rogers, S.L.1
Doody, R.S.2
Mohs, R.C.3
Friedhoff, L.T.4
-
3
-
-
0031883716
-
A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease
-
Donepezil Study Group
-
Rogers S.L., Farlow M.R., Doody R.S., Mohs R., Friedhoff L.T., and Donepezil Study Group. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 50 (1998) 136-145
-
(1998)
Neurology
, vol.50
, pp. 136-145
-
-
Rogers, S.L.1
Farlow, M.R.2
Doody, R.S.3
Mohs, R.4
Friedhoff, L.T.5
-
4
-
-
0029790469
-
Observations and suggestions on antidementia drug development
-
Leber P. Observations and suggestions on antidementia drug development. Alzheimer Dis Assoc Disord 10 Suppl1 (1996) 31-35
-
(1996)
Alzheimer Dis Assoc Disord
, vol.10
, Issue.Suppl1
, pp. 31-35
-
-
Leber, P.1
-
5
-
-
0033679259
-
A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease
-
Farlow M., Anand R., Messina Jr. J., Hartman R., and Veach J. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease. Eur Neurol 44 (2000) 236-241
-
(2000)
Eur Neurol
, vol.44
, pp. 236-241
-
-
Farlow, M.1
Anand, R.2
Messina Jr., J.3
Hartman, R.4
Veach, J.5
-
6
-
-
0035103036
-
Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease
-
Donepezil Study Group
-
Doody R.S., Geldmacher D.S., Gordon B., Perdomo C.A., Pratt R.D., and Donepezil Study Group. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol 58 (2001) 427-433
-
(2001)
Arch Neurol
, vol.58
, pp. 427-433
-
-
Doody, R.S.1
Geldmacher, D.S.2
Gordon, B.3
Perdomo, C.A.4
Pratt, R.D.5
-
7
-
-
1042291157
-
The cognitive benefits of galantamine are sustained for at least 36 months
-
Raskind M.A., Peskind E.R., Truyen L., Kershaw P., and Damaraju C.R.V. The cognitive benefits of galantamine are sustained for at least 36 months. Arch Neurol 61 (2004) 252-256
-
(2004)
Arch Neurol
, vol.61
, pp. 252-256
-
-
Raskind, M.A.1
Peskind, E.R.2
Truyen, L.3
Kershaw, P.4
Damaraju, C.R.V.5
-
9
-
-
33645756861
-
Do cholinergic therapies have disease-modifying effects in Alzheimer's disease?
-
Sabbagh M.N., Farlow M.R., Relkin N., and Beach T.G. Do cholinergic therapies have disease-modifying effects in Alzheimer's disease?. Alzheimer's & Dementia 2 (2006) 118-125
-
(2006)
Alzheimer's & Dementia
, vol.2
, pp. 118-125
-
-
Sabbagh, M.N.1
Farlow, M.R.2
Relkin, N.3
Beach, T.G.4
-
11
-
-
0030865454
-
Slowing the progression of Alzheimer disease: methodologic issues
-
Leber P. Slowing the progression of Alzheimer disease: methodologic issues. Alzheimer Dis Assoc Disord 11 (1997) S10-S21
-
(1997)
Alzheimer Dis Assoc Disord
, vol.11
-
-
Leber, P.1
-
12
-
-
0032237793
-
Clinical trial designs for demonstrating disease-course-altering effects in dementia
-
Whitehouse P.J., Kittner B., Roessner M., Rossor M., Sano M., Thal L., et al. Clinical trial designs for demonstrating disease-course-altering effects in dementia. Alzheimer Dis Assoc Disord 12 (1998) 281-294
-
(1998)
Alzheimer Dis Assoc Disord
, vol.12
, pp. 281-294
-
-
Whitehouse, P.J.1
Kittner, B.2
Roessner, M.3
Rossor, M.4
Sano, M.5
Thal, L.6
-
13
-
-
0034099077
-
Using serial-registered brain magnetic resonance imaging to measure disease progression in Alzheimer disease: power calculations and estimates of sample size to detect treatment effects
-
Fox N.C., Cousens S., Scahill R., Harvey R.J., and Rosser M.N. Using serial-registered brain magnetic resonance imaging to measure disease progression in Alzheimer disease: power calculations and estimates of sample size to detect treatment effects. Arch Neurol 57 (2000) 339-344
-
(2000)
Arch Neurol
, vol.57
, pp. 339-344
-
-
Fox, N.C.1
Cousens, S.2
Scahill, R.3
Harvey, R.J.4
Rosser, M.N.5
-
14
-
-
23944435182
-
Changing patient characteristics and survival experience in an Alzheimer's center patient cohort
-
Doody R., Pavlik V., Massman P., Kenan M., Yeh S., Powell S., et al. Changing patient characteristics and survival experience in an Alzheimer's center patient cohort. Dement Geriatr Cogn Disord 20 (2005) 198-208
-
(2005)
Dement Geriatr Cogn Disord
, vol.20
, pp. 198-208
-
-
Doody, R.1
Pavlik, V.2
Massman, P.3
Kenan, M.4
Yeh, S.5
Powell, S.6
-
15
-
-
0035099794
-
A method for estimating progression rates in Alzheimer disease
-
Doody R.S., Massman P., and Dunn J.K. A method for estimating progression rates in Alzheimer disease. Arch Neurol 58 (2001) 449-454
-
(2001)
Arch Neurol
, vol.58
, pp. 449-454
-
-
Doody, R.S.1
Massman, P.2
Dunn, J.K.3
-
16
-
-
0035001864
-
Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer's disease
-
Doody R.S., Dunn J.K., Clark C.M., Farlow M., Foster N.L., Liao T., et al. Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer's disease. Dement Geriatr Cogn Disord 12 (2001) 295-300
-
(2001)
Dement Geriatr Cogn Disord
, vol.12
, pp. 295-300
-
-
Doody, R.S.1
Dunn, J.K.2
Clark, C.M.3
Farlow, M.4
Foster, N.L.5
Liao, T.6
-
17
-
-
0036185530
-
Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease
-
Lopez O.L., Becker J.T., Wisniewski S., Saxton J., Kaufer D.I., and DeKosky S.T. Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease. J Neurol Neurosurg Psychiatry 72 (2002) 310-314
-
(2002)
J Neurol Neurosurg Psychiatry
, vol.72
, pp. 310-314
-
-
Lopez, O.L.1
Becker, J.T.2
Wisniewski, S.3
Saxton, J.4
Kaufer, D.I.5
DeKosky, S.T.6
-
18
-
-
38049039184
-
Exposure to antidementia drugs slows clinical progression of Alzheimer's disease (AD)
-
Rountree S., Chan W., Doody R., Pavlik V., Darby E., Saddiqui S., et al. Exposure to antidementia drugs slows clinical progression of Alzheimer's disease (AD). Ann Neurol 62 Suppl 11 (2007) S55
-
(2007)
Ann Neurol
, vol.62
, Issue.SUPPL. 11
-
-
Rountree, S.1
Chan, W.2
Doody, R.3
Pavlik, V.4
Darby, E.5
Saddiqui, S.6
-
19
-
-
35848962080
-
Disease-modifying therapies for Alzheimer disease. challenges to early intervention
-
Cummings J., Doody R., and Clark C. Disease-modifying therapies for Alzheimer disease. challenges to early intervention. Neurology 69 (2007) 1622-1634
-
(2007)
Neurology
, vol.69
, pp. 1622-1634
-
-
Cummings, J.1
Doody, R.2
Clark, C.3
-
20
-
-
38049012255
-
Model-based longitudinal data analysis can lead to more efficient drug development. a case study
-
EPub April 27
-
Jadhav P.R., and Gobburu J.V.S. Model-based longitudinal data analysis can lead to more efficient drug development. a case study. FDA Science Forum (2005) EPub April 27
-
(2005)
FDA Science Forum
-
-
Jadhav, P.R.1
Gobburu, J.V.S.2
|